The introduction of this website is a direct result of the increased demand for NAMSA’s integrated medical device development services throughout China. Asia-Pacific’s second largest growth territory, China, is expected to grow steadily at a 5.9 percent compound annual growth rate to $57 billion by 2022, according to GlobalData.
“NAMSA China is pleased to introduce our first-ever Chinese language website to better serve our APAC clients. This user-friendly and information-filled resource will not only help support our significant growth in the region, but will also allow local manufacturers to more easily identify a proven, single source solution for efficient and cost-effective development and successful market introductions,” commented Samuel Tong, general manager, NAMSA China.
NAMSA, with three locations throughout China, is a leader within the Contract Research Organization (CRO) industry, and has a track record of delivering savings of up to 23 months and more than $17 million throughout the product development continuum. For over 50 years, NAMSA has focused on the use of client resources and the delivery of high-quality development services, and has assisted thousands of customers to successfully launch life-changing medical products around the world.
NAMSA is a Medical Research Organization (MRO), accelerating medical device product development through integrated laboratory, clinical research and regulatory consulting services. Driven by its regulatory expertise, NAMSA’s MRO Approach plays an important role in translational research, applying a unique combination of disciplines—consulting, regulatory, preclinical, toxicology, microbiology, chemistry, clinical and quality—to move clients’ products through the development process, and continue to provide support through commercialization to post-market requirements anywhere in the world.
NAMSA operates 13 offices throughout North America, Europe, the Middle East and Asia, and employs nearly 1,000 laboratory, clinical, and consulting associates.